Navigation Links
RxElite Registration Statement Suspended
Date:1/4/2008

MERIDIAN, Idaho, Jan. 4 /PRNewswire-FirstCall/ -- RxElite, Inc. (OTC Bulletin Board: RXEI), a developer, manufacturer, and marketer of specialty generic prescription drug products, announced today the suspension of their registration statement covering the resale of 53,747,555 shares. The suspension is permitted by the Securities and Exchange Commission in certain cases. The company requested this suspension to protect investors due to material non-public information relating to an acquisition. The Company will release information regarding the acquisition as soon as practical. The suspension of this registration statement is allowable for up to 90 days.

About RxElite, Inc.

RxElite, Inc. develops, manufactures, and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics, and injectable drugs), and transdermal patch products.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving known and unknown risks, delays, and uncertainties that may cause our actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks, delays, and uncertainties include, but are not limited to: risks associated with the uncertainty of future financial results, our reliance on our sole supplier, the limited diversification of our product offerings, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.

Contacts:

Corporate Information

Ph: (208) 288-5550

Toll Free: (800) 414-1901

Fax: (208) 288-1191

Investor Relations

Charlie Forshee, 215-885-4981

investorrelations@rxelite.com

Segue Ventures LLC


'/>"/>
SOURCE RxElite, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. RxElite Files Registration Statement with Securities and Exchange Commission
2. RxElite Announces 3rd Quarter Financials Conference Call
3. RxElite Registration Statement Declared Effective by Securities and Exchange Commission
4. Glades General Hospital First in Palm Beach County to Provide On-Site Electronic Birth Registration
5. MedCom USAs Subsidiary Card Activation Technologies, Inc.s SB2 Registration Declared Effective by SEC
6. Gentiva(R) Health Services Files Universal Shelf Registration Statement
7. PA Governors Occupational Safety and Health Conference Still Accepting Registrations
8. Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock
9. Pearson Introduces Smart Technology for Collecting Patient Registration Information
10. FDA Approves the Opening of a Phase II Registration Protocol Using REXIN-G(R) for Osteosarcoma in California U.S.A.
11. HEI, Inc. Initiates Delisting and Deregistration of Its Shares on NASDAQ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2017)... ... July 22, 2017 , ... More than 130,000 Anterior Cruciate ... requiring pain medication after three months post-operatively. However, researchers presenting their work at ... Toronto, Ontario, Canada found that those patients who were filling opioid prescriptions prior ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Wettstein Agencies, ... communities in the greater Denver region, is announcing a charity drive to help ... rare kind of epilepsy. , Until a few months ago, Dominik was a ...
(Date:7/21/2017)... Minnesota (PRWEB) , ... July 21, 2017 , ... ... BWBR recently were selected to renovate and improve the Ramsey County Medical Examiners ... adjacent to Regions Hospital, the $2.5 million project is scheduled to start in ...
(Date:7/21/2017)... ... July 21, 2017 , ... Bernard R. Bach, Jr., MD, ... the American Orthopaedic Society of Sports Medicine (AOSSM) , received the 2017 Robert ... Annual Meeting in Toronto, Canada. This prestigious award is given annually to honor those ...
(Date:7/21/2017)... ORLEANS, La. (PRWEB) , ... July 21, 2017 ... ... to allow 4th-year medical students improve their chances of acceptance to a residency ... for those who have earned degrees outside the U.S. , According to data ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... 2017  Sysmex America, Inc., a leading provider ... as well as middleware information systems technology, today ... quality assurance easier and more risk free than ... for the innovation that it delivers to the ... assurance processes to a new level with automated, ...
(Date:7/11/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... on the development of oral drug delivery systems, announced ... has agreed to schedule an End-of-Phase II meeting with ... its oral insulin capsule ORMD-0801 in the treatment of ... and secondary endpoints by indicating a statistically significant lowering ...
(Date:7/10/2017)... The Institute for In Vitro Sciences (IIVS), ... of a VITROCELL® inhalation exposure system thanks to a ... device, which is designed to replace animals in inhalation ... to airborne test materials in an environment that mimics ... for testing combustible tobacco products, as well as next ...
Breaking Medicine Technology: